September 15, 2017 10:09 AM EDT

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

Shehla Shakoor

Managing Director

⇨ BioMarin says that the FDA is indicating that it won’t be holding a panel review for pegvaliase as a new treatment for phenylketonuria …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

Shehla Shakoor

Managing Director

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Why Regeneron is buying 23andMe

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Regeneron plans to buy 23andMe for $256M

Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

FDA takes a pass on peg­valiase pan­el; Flex­ion ter­mi­nates an old As­traZeneca pact

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact